Indication
x POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

IS YOUR PATIENT PROGRESSING ON
REVLIMID® (lenalidomide)?

Now Is the Time for a Different IMiD®.

In patients with RRMM who received REVLIMID® (lenalidomide) and a PI.

Pd: An approved doublet therapy of POMALYST + low-dose dex

  • For adult patients with multiple myeloma (MM) who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on or within 60 days of completion of the last therapy
  • A proven doublet therapy built on a FOUNDATION of POMALYST in patients with RRMM who received REVLIMID® (lenalidomide)* and a PI

*Please see full Prescribing Information, including Boxed WARNINGS, for REVLIMID.

dex, dexamethasone; IMiD, immunomodulatory drug; Pd, POMALYST + dexamethasone; RRMM, relapsed/refractory multiple myeloma.

Reference: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp.

Pd was studied in patients who had
received ≥2 prior therapies, including REVLIMID and a PI.

See the Full Trial Design